NCT03327740 - PRJ2203: Dolutegravir Post Authorization Safety Study (PASS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions

Infection, Human Immunodeficiency Virus I

Interventions

DRUG

DTG based ARV regimen with ABC

ARV regimens containing DTG and ABC

DRUG

DTG based ARV regimen without ABC

DTG based ARV regimens that do not contain ABC

DRUG

RAL or EGV based ARV regimens with ABC

RAL or EGV based regimens containing ABC

DRUG

RAL or EGV based regimens without ABC

RAL or EGV based ARV regimens that do not contain ABC

DRUG

Any other DTG based ARV regimen as monotherapy

Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.